| Statins in the prevention of dementia and Alzheimer's disease: a meta‐analysis of observational studies and an assessment of confounding WB Wong, VW Lin, D Boudreau, EB Devine Pharmacoepidemiology and drug safety 22 (4), 345-358, 2013 | 143 | 2013 |
| Cost effectiveness of pharmacogenomics: a critical and systematic review WB Wong, JJ Carlson, R Thariani, DL Veenstra Pharmacoeconomics 28, 1001-1013, 2010 | 128 | 2010 |
| Assessment of costs associated with adverse events in patients with cancer W Wong, YM Yim, A Kim, M Cloutier, M Gauthier-Loiselle, ... PLOS one 13 (4), e0196007, 2018 | 108 | 2018 |
| The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007) WB Wong, SD Ramsey, WE Barlow, LP Garrison Jr, DL Veenstra Contemporary clinical trials 33 (6), 1117-1123, 2012 | 60 | 2012 |
| ALK testing trends and patterns among community practices in the United States PB Illei, W Wong, N Wu, L Chu, R Gupta, K Schulze, MA Gubens JCO Precision Oncology 2, 1-11, 2018 | 41 | 2018 |
| Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer JJ Carlson, K Suh, P Orfanos, W Wong Pharmacoeconomics 36, 495-504, 2018 | 34 | 2018 |
| The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib JJ Carlson, W Canestaro, A Ravelo, W Wong Journal of Medical Economics 20 (7), 671-677, 2017 | 32 | 2017 |
| Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer C Burudpakdee, W Wong, A Seetasith, FA Corvino, W Yeh, M Gubens Lung Cancer 119, 103-111, 2018 | 30 | 2018 |
| Trends in use of next-generation sequencing in patients with solid tumors by race and ethnicity after implementation of the Medicare national coverage determination DM Sheinson, WB Wong, CS Meyer, S Stergiopoulos, KT Lofgren, ... JAMA Network Open 4 (12), e2138219-e2138219, 2021 | 22 | 2021 |
| Value of precision medicine in advanced non‐small cell lung cancer: Real‐world outcomes associated with the use of companion diagnostics A John, RA Shah, WB Wong, CE Schneider, M Alexander The Oncologist 25 (11), e1743-e1752, 2020 | 22 | 2020 |
| Association between Medicare's national coverage determination and utilization of next-generation sequencing DM Sheinson, WB Wong, C Flores, S Ogale, CP Gross JCO Oncology Practice 17 (11), e1774-e1784, 2021 | 21 | 2021 |
| Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology … MS Walker, W Wong, A Ravelo, PJE Miller, LS Schwartzberg Health and quality of life outcomes 15 (1), 1-11, 2017 | 20 | 2017 |
| Prioritization in Comparative Effectiveness Research: the CANCERGEN experience in cancer genomics R Thariani, W Wong, JJ Carlson, L Garrison, S Ramsey, PA Deverka, ... Medical care 50 (5), 388, 2012 | 19 | 2012 |
| Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer D Sheinson, WB Wong, N Wu, AS Mansfield Lung Cancer 143, 86-92, 2020 | 18 | 2020 |
| Oncologists’ perceptions of drug affordability using NCCN evidence blocks: results from a national survey B Shah-Manek, W Wong, A Ravelo, M DiBonaventura Journal of Managed Care & Specialty Pharmacy 24 (6), 565-571, 2018 | 17 | 2018 |
| Effect of brain metastasis on patient-reported outcomes in advanced NSCLC treated in real-world community oncology settings MS Walker, W Wong, A Ravelo, PJE Miller, LS Schwartzberg Clinical Lung Cancer 19 (2), 139-147, 2018 | 16 | 2018 |
| Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC RC Doebele, L Perez, H Trinh, M Martinec, R Martina, T Riehl, MG Krebs, ... Journal of Comparative Effectiveness Research 10 (17), 1271-1282, 2021 | 15 | 2021 |
| Are National Comprehensive Cancer Network evidence block affordability ratings representative of real-world costs? An evaluation of advanced Non–small-cell lung cancer JT Cohen, PJ Lin, DM Sheinson, WB Wong, N Wu, YM Yim, SD Ramsey Journal of oncology practice 15 (11), e948-e956, 2019 | 14 | 2019 |
| Predictors, resource utilization, and short-term costs of laser trabeculoplasty versus medication management in open-angle glaucoma NM Schultz, WB Wong, AL Coleman, DC Malone American Journal of Ophthalmology 168, 78-85, 2016 | 14 | 2016 |
| Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer JJ Carlson, WB Wong, DL Veenstra, C Reyes Journal of Medical Economics 14 (2), 159-166, 2011 | 14 | 2011 |
